Front line treatment of elderly multiple myeloma in the era of novel agents

Marie-Dominique Venon2, Aldo M Roccaro1,3, Julie Gay2, Anne-Sophie Moreau1,2, Remy Dulery2, Thierry Facon2, Irene M Ghobrial1, Xavier Leleu1,21Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 2Service des Maladies du Sang, Hopital Huriez, CHRU...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marie-Dominique Venon, Aldo M Roccaro, Julie Gay, Anne-Sophie Moreau, Remy Dulery, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c3d984edaf5f40e592669015b0aade17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3d984edaf5f40e592669015b0aade17
record_format	dspace
spelling	oai:doaj.org-article:c3d984edaf5f40e592669015b0aade172021-12-02T11:44:10ZFront line treatment of elderly multiple myeloma in the era of novel agents1177-54751177-5491https://doaj.org/article/c3d984edaf5f40e592669015b0aade172008-10-01T00:00:00Zhttp://www.dovepress.com/front-line-treatment-of-elderly-multiple-myeloma-in-the-era-of-novel-a-a2524https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Marie-Dominique Venon2, Aldo M Roccaro1,3, Julie Gay2, Anne-Sophie Moreau1,2, Remy Dulery2, Thierry Facon2, Irene M Ghobrial1, Xavier Leleu1,21Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 2Service des Maladies du Sang, Hopital Huriez, CHRU, Lille, France; 3Units of Blood Diseases and Cell Therapies, University of Bresica, Medical School, Bresica, ItalyAbstract: Melphalan combined with prednisone (MP) has long been the historical treatment of reference for a large proportion of elderly myeloma (MM) patients ineligible for autologous stem cell transplantation, and is still the backbone of new regimens that include the new era of novel agents. Melphalan&ndash;prednisone&ndash;thalidomide (MPT) and melphalan&ndash;prednisone&ndash;bortezomib (Velcade&reg;, MPV), proved superior to MP, currently appear to be the treatments of choice for this population. In the near future melphalan&ndash;prednisone&ndash;lenalidomide (Revlimid&reg;, MPR) will also provide a third therapeutic option (MPT, MPV, and MPR), in elderly multiple myeloma, eventually. These options could lead to more personalized treatment approaches, based on patient comorbidities, as the three novel agents have somewhat different toxicity profiles. Dexamethasone-based regimen is another option and questions regarding the relative efficacy of melphalan-based versus low-dose dexamethasone-based regimens will require randomized phase III trials. More intensive approaches with new drug combinations or with the incorporation of polyethylene glycolated (PEGylated) liposomal doxorubicin will also require additional studies. Additionally, the important issue of maintenance treatment needs to be further investigated. These new and emerging therapies offer multiple effective treatment options for MM patients and greatly enhanced treatment strategies for clinicians.Keywords: multiple myeloma, elderly, bortezomib, thalidomide, revlimid, IMiDs, supportive care Marie-Dominique VenonAldo M RoccaroJulie GayAnne-Sophie MoreauRemy Duleryet alDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 99-109 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Marie-Dominique Venon Aldo M Roccaro Julie Gay Anne-Sophie Moreau Remy Dulery et al Front line treatment of elderly multiple myeloma in the era of novel agents
description	Marie-Dominique Venon2, Aldo M Roccaro1,3, Julie Gay2, Anne-Sophie Moreau1,2, Remy Dulery2, Thierry Facon2, Irene M Ghobrial1, Xavier Leleu1,21Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 2Service des Maladies du Sang, Hopital Huriez, CHRU, Lille, France; 3Units of Blood Diseases and Cell Therapies, University of Bresica, Medical School, Bresica, ItalyAbstract: Melphalan combined with prednisone (MP) has long been the historical treatment of reference for a large proportion of elderly myeloma (MM) patients ineligible for autologous stem cell transplantation, and is still the backbone of new regimens that include the new era of novel agents. Melphalan&ndash;prednisone&ndash;thalidomide (MPT) and melphalan&ndash;prednisone&ndash;bortezomib (Velcade&reg;, MPV), proved superior to MP, currently appear to be the treatments of choice for this population. In the near future melphalan&ndash;prednisone&ndash;lenalidomide (Revlimid&reg;, MPR) will also provide a third therapeutic option (MPT, MPV, and MPR), in elderly multiple myeloma, eventually. These options could lead to more personalized treatment approaches, based on patient comorbidities, as the three novel agents have somewhat different toxicity profiles. Dexamethasone-based regimen is another option and questions regarding the relative efficacy of melphalan-based versus low-dose dexamethasone-based regimens will require randomized phase III trials. More intensive approaches with new drug combinations or with the incorporation of polyethylene glycolated (PEGylated) liposomal doxorubicin will also require additional studies. Additionally, the important issue of maintenance treatment needs to be further investigated. These new and emerging therapies offer multiple effective treatment options for MM patients and greatly enhanced treatment strategies for clinicians.Keywords: multiple myeloma, elderly, bortezomib, thalidomide, revlimid, IMiDs, supportive care
format	article
author	Marie-Dominique Venon Aldo M Roccaro Julie Gay Anne-Sophie Moreau Remy Dulery et al
author_facet	Marie-Dominique Venon Aldo M Roccaro Julie Gay Anne-Sophie Moreau Remy Dulery et al
author_sort	Marie-Dominique Venon
title	Front line treatment of elderly multiple myeloma in the era of novel agents
title_short	Front line treatment of elderly multiple myeloma in the era of novel agents
title_full	Front line treatment of elderly multiple myeloma in the era of novel agents
title_fullStr	Front line treatment of elderly multiple myeloma in the era of novel agents
title_full_unstemmed	Front line treatment of elderly multiple myeloma in the era of novel agents
title_sort	front line treatment of elderly multiple myeloma in the era of novel agents
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/c3d984edaf5f40e592669015b0aade17
work_keys_str_mv	AT mariedominiquevenon frontlinetreatmentofelderlymultiplemyelomaintheeraofnovelagents AT aldomroccaro frontlinetreatmentofelderlymultiplemyelomaintheeraofnovelagents AT juliegay frontlinetreatmentofelderlymultiplemyelomaintheeraofnovelagents AT annesophiemoreau frontlinetreatmentofelderlymultiplemyelomaintheeraofnovelagents AT remydulery frontlinetreatmentofelderlymultiplemyelomaintheeraofnovelagents AT etal frontlinetreatmentofelderlymultiplemyelomaintheeraofnovelagents
_version_	1718395307762384896

Front line treatment of elderly multiple myeloma in the era of novel agents

Ejemplares similares